Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseases

1 Feb 2014

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neurogenetic and Muscular Disorders Research
Share to RNA modifications and cancer
Share to RNA Research and Splicing

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 24486759
DOI: 10.1016/j.yexcr.2014.01.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antisense-mediated exon skipping: Taking advantage of a trick from Mother Nature to treat rare genetic diseasesPMID 24486759Read ↗

Overview on applications of antisense-mediated exon skipping.Semantic proximity Read ↗

Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic diseases.Semantic proximity Read ↗

Antisense Oligonucleotide-Mediated Exon-skipping Therapies: Precision Medicine Spreading from Duchenne Muscular DystrophySemantic proximity Read ↗

194th ENMC international workshop. 3rd ENMC workshop on exon skipping: Towards clinical application of antisense-mediated exon skipping for Duchenne muscular dystrophy 8–10 December 2012, Naarden, The NetherlandsSemantic proximity Read ↗

Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disordersSemantic proximity Read ↗

Practical Recommendations for the Selection of Patients for Individualized Splice-Switching ASO-Based TreatmentsSemantic proximity Read ↗

Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments.Semantic proximity Read ↗

Translational and Regulatory Challenges for Exon Skipping TherapiesSemantic proximity Read ↗

Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatmentsSemantic proximity Read ↗

New approaches to the treatment of orphan genetic disorders: Mitigating molecular pathologies using chemicals.Semantic proximity Read ↗

Making antisense of splicing.Semantic proximity Read ↗

A scalable platform for exon-skipping antisense oligonucleotide therapy development for inborn genetic diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.